Immutep Ltd. Aktie

Immutep Limited, an Australian biotechnology company incorporated in 1987 and formerly known as Prima BioMed Ltd until its name change in November 2017, focuses its research and development efforts on pharmaceutical products. The company primarily develops immunotherapeutic products designed to treat cancer and autoimmune diseases. Its lead therapeutic candidate, eftilagimod alpha (or efti/IMP321), is a recombinant protein currently in Phase IIb clinical trials as a chemo-immunotherapy combination for metastatic breast cancer. Immutep's pipeline includes several other promising therapies in different clinical stages. These include TACTI-002, which is undergoing Phase II clinical evaluation for head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003, also for HNSCC and currently in Phase IIb; and INSIGHT-003 and INSIGHT-005, which are in Phase I and Phase I/IIa trials respectively, both targeting solid tumors. For autoimmune conditions, Immutep is advancing IMP761, an agonist of lymphocyte activation gene 3, and IMP731, a depleting antibody that eliminates T cells involved in autoimmunity. Additionally, IMP701 is an antagonist antibody designed to stimulate T cell proliferation in cancer patients. The company maintains strategic collaboration agreements with a number of partners, such as GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. Immutep is headquartered in Sydney, Australia.